Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Increases By 67.1%

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) saw a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 66,000 shares, a growth of 67.1% from the October 31st total of 39,500 shares. Approximately 9.7% of the company’s shares are sold short. Based on an average trading volume of 58,000 shares, the short-interest ratio is currently 1.1 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright raised their target price on shares of Cadrenal Therapeutics from $3.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, November 11th.

Cadrenal Therapeutics Trading Up 3.2 %

NASDAQ CVKD opened at $14.15 on Friday. The firm has a market capitalization of $23.49 million, a PE ratio of -2.12 and a beta of 1.52. The stock’s fifty day moving average price is $14.59. Cadrenal Therapeutics has a 52 week low of $5.40 and a 52 week high of $32.55.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.